Jacqueline Garcia, MD
Enriched profileAssociate Professor of Medicine, Harvard Medical School; Medical Oncologist, Adult Leukemia Program, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Jacqueline Garcia is Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Adult Leukemia Program, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 412 publications with 6,883 citations (h-index 36); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Jacqueline Garcia, M.D., is Associate Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. The public record shows 412 publications with 6,883 citations (h-index 36), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 17 companies, 2 NIH-funded awards (2020–2024).
- Most recent indexed publication: 2026 · Leukemia & lymphoma
- Top research focus: Acute Myeloid Leukemia Research
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 50 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 84.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Sponsor: Jacqueline Garcia, MD
- BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 1 Sept 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20255 payments
- ABBVIE INC.Program year20254 payments
- Syndax Pharmaceuticals, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.9%Kinase inhibitor21.7%Jakafi50%Imatinib Mesylate25%Vonjo25%Part D<11 patientsJanus-associated kinase (JAK) inhibitors19%Ojjaara100%Part D<11 patientsDermatology
24%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.8%Acyclovir100%Part D≥17 patientsPolyene Antifungal4.3%Nystatin100%Part D<11 patientsMusculoskeletal
12%Xanthine oxidase inhibitor12%Allopurinol100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
2 NIH research awards on record, funded 2020–2024 per NIH RePORTER. The latest:
- Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
Dana-Farber Cancer Inst
FY2024$258,561K08CA245209 - Investigating Astrocytic Glutamate and Potassium Dynamics in the Healthy and Injured Brain
Tufts University Boston
FY2024$45,729F99NS134140 - Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
Dana-Farber Cancer Inst
FY2023$258,561K08CA245209
Congress activity
Updated 1 Sept 2026
99 congress contributions (2017–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in <i>IDH1</i> -mutated acute myeloid leukemia (AML).
ASCO Annual Meeting
ASCO2026Co-author - Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaArticle2,831 citations2020
- 02
- 03
- 04
- 05
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jacqueline-garcia-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
physicianresources.dana-farber.org/videos/jacqueline-garcia-md-on-oral-maintenance-therapy-in-aml/mds-patients
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗ - Other
aamds.org/bio/jacqueline-garcia-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗ - Other
vjhemonc.com/speaker/jacqueline-garcia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- M.D.
University of Illinois at Chicago College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Internal Medicine Residency
University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Hematology and Oncology Fellowship
Stanford University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Panel Member
American Society of Hematology 2025 Guidelines for Treating Newly Diagnosed Acute Myeloid Leukemia in Older Adults
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmc.ncbi.nlm.nih.gov ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providers.dana-farberbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- Contributor/interviewee
OncLive oncology news platform (author page aggregating video interviews and articles)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute